Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Neoplasms 8 Endometrial Neoplasms 6 Neoplasm Metastasis 5 Brain Neoplasms 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Meningioma 3 Glioblastoma 3 Sarcoma 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Lymphoma, Non-Hodgkin 2 Carcinoma, Non-Small-Cell Lung 2 Urologic Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Retinoblastoma 1 Recurrence 1 Pathologic Complete Response 1 Osteosarcoma 1 Neoplasms, Squamous Cell 1 Neoplasm, Residual 1 Multiple Myeloma 1

Interventions

Fulvestrant 5 Letrozole 3 Capecitabine 3 ribociclib 2 exemestane 2 dalpiciclib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 Anastrozole 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pegfilgrastim 1 palbociclib 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Liposomes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Metastatic × abemaciclib × Clear all

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡